那不勒斯预后评分在肺癌预后中的作用：一项meta分析。

IF 1.9 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2025-09-09 DOI:10.1080/1354750X.2025.2556171

Junrong Yang, Hui Li, Liangqin Li, Jing Lv

{"title":"那不勒斯预后评分在肺癌预后中的作用：一项meta分析。","authors":"Junrong Yang, Hui Li, Liangqin Li, Jing Lv","doi":"10.1080/1354750X.2025.2556171","DOIUrl":null,"url":null,"abstract":"Purpose: To clarify the association of pretreatment Naples prognostic score (NPS) with long-term survival among lung cancer patients.Methods: EMBASE, Web of Science, PubMed and CNKI databases were searched up to April 16, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis stratified by the pathological type and treatment was performed.Results: Twelve studies with 3089 patients were included and most patients were from China. Pooled results demonstrated that elevated NPS was related to poor OS (HR = 2.82, 95% CI: 1.88-4.25, P < 0.001), PFS (HR = 2.75, 95% CI: 1.89-4.01, P < 0.001) and CSS (HR = 3.5, 95% CI: 1.6-7.9, P = 0.002). Besides, subgroup analysis based on the pathological type [non-small cell lung cancer (NSCLC) vs small cell lung cancer (SCLC)] and treatment (surgery vs non-surgery) manifested similar results.Conclusion: Pretreatment NPS is associated with long-term prognosis in lung cancer and patients with elevated NPS are more likely to experience poor survival. However, more studies are needed to verify above findings due to limitations in this meta-analysis.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-8"},"PeriodicalIF":1.9000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic role of Naples prognostic score in lung cancer: a meta-analysis.\",\"authors\":\"Junrong Yang, Hui Li, Liangqin Li, Jing Lv\",\"doi\":\"10.1080/1354750X.2025.2556171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To clarify the association of pretreatment Naples prognostic score (NPS) with long-term survival among lung cancer patients.Methods: EMBASE, Web of Science, PubMed and CNKI databases were searched up to April 16, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis stratified by the pathological type and treatment was performed.Results: Twelve studies with 3089 patients were included and most patients were from China. Pooled results demonstrated that elevated NPS was related to poor OS (HR = 2.82, 95% CI: 1.88-4.25, P < 0.001), PFS (HR = 2.75, 95% CI: 1.89-4.01, P < 0.001) and CSS (HR = 3.5, 95% CI: 1.6-7.9, P = 0.002). Besides, subgroup analysis based on the pathological type [non-small cell lung cancer (NSCLC) vs small cell lung cancer (SCLC)] and treatment (surgery vs non-surgery) manifested similar results.Conclusion: Pretreatment NPS is associated with long-term prognosis in lung cancer and patients with elevated NPS are more likely to experience poor survival. However, more studies are needed to verify above findings due to limitations in this meta-analysis.\",\"PeriodicalId\":8921,\"journal\":{\"name\":\"Biomarkers\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1354750X.2025.2556171\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2025.2556171","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的探讨预处理那不勒斯预后评分（NPS）与肺癌患者长期生存的关系。方法检索截止2024年4月16日的EMBASE、Web of Science、PubMed和CNKI数据库。主要结局包括总生存期（OS）、无进展生存期（PFS）和癌症特异性生存期（CSS）。合并危险比（hr）和95%可信区间（ci），并按病理类型和治疗方法进行亚组分析。结果纳入12项研究，共3089例患者，大多数患者来自中国。综合结果显示，NPS升高与不良OS相关（HR = 2.82, 95% CI: 1.88-4.25）。结论预处理NPS与肺癌的长期预后相关，NPS升高的患者更容易出现不良生存。然而，由于本荟萃分析的局限性，需要更多的研究来验证上述发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic role of Naples prognostic score in lung cancer: a meta-analysis.

Purpose: To clarify the association of pretreatment Naples prognostic score (NPS) with long-term survival among lung cancer patients.

Methods: EMBASE, Web of Science, PubMed and CNKI databases were searched up to April 16, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis stratified by the pathological type and treatment was performed.

Results: Twelve studies with 3089 patients were included and most patients were from China. Pooled results demonstrated that elevated NPS was related to poor OS (HR = 2.82, 95% CI: 1.88-4.25, P < 0.001), PFS (HR = 2.75, 95% CI: 1.89-4.01, P < 0.001) and CSS (HR = 3.5, 95% CI: 1.6-7.9, P = 0.002). Besides, subgroup analysis based on the pathological type [non-small cell lung cancer (NSCLC) vs small cell lung cancer (SCLC)] and treatment (surgery vs non-surgery) manifested similar results.

Conclusion: Pretreatment NPS is associated with long-term prognosis in lung cancer and patients with elevated NPS are more likely to experience poor survival. However, more studies are needed to verify above findings due to limitations in this meta-analysis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.